Literature DB >> 10730925

Reappraisal of biochemical hepatitis C activity in hemodialysis patients.

N Yuki1, H Ishida, T Inoue, T Tabata, Y Matsushita, H Kishimoto, M Kato, M Masuzawa, Y Sasaki, N Hayashi, M Hori.   

Abstract

We reappraised biochemical hepatitis C activity in hemodialysis patients in comparison with normal controls. A total of 111 hemodialysis patients and 66 healthy volunteer blood donors with hepatitis C virus (HCV) infection were consecutively enrolled. Serum alanine aminotransferase (ALT) levels were normal (< or =45 U/L) in 103 (93%) hemodialysis patients and 34 (52%) donors (p < 0.001). HCV viremic levels were lower in the hemodialysis group (p = 0.044), with no difference in the HCV genotype prevalence. During two-year follow-up, 60 (67%) of 90 hemodialysis patients and 13 (26%) of 50 donors showed persistently normal ALT levels (p < 0.001). For hemodialysis patients, however, the upper normal limit of ALT activity was reset at 25 U/L corresponding to the mean + 2 x SD for the normalized ALT distribution in 400 control patients. The adjusted ALT levels were initially normal in 73 (66%) hemodialysis patients and persistently normal in 19 (21%). Thus, ALT levels were the same for the two groups. GB virus C (GBV-C)/hepatitis G virus (HGV) coinfection found only in the hemodialysis group (10/111) had no influence on the disease. A relationship was noted between low disease activity and female gender in both groups. These findings indicate that biochemical hepatitis C activity in hemodialysis patients is similar to that in normal controls and should be monitored based on adjusted ALT levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10730925     DOI: 10.1097/00004836-200003000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Mikio Zeniya; Etsuko Iio; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2016-02-12       Impact factor: 7.527

2.  Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis.

Authors:  Isabella Ramos de Oliveira Liberato; Edmundo Pessoa de Almeida Lopes; Maria Alina Gomes de Mattos Cavalcante; Tiago Costa Pinto; Izolda Fernades Moura; Luiz Loureiro Júnior
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

3.  Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients.

Authors:  Beatris Maria Vidales-Braz; Naylê Maria Oliveira da Silva; Rubens Lobato; Fabiana Nunes Germano; Luiza Dias da Mota; Elvino J G Barros; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2015-02-03       Impact factor: 4.099

Review 4.  Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review.

Authors:  Luís Henrique Bezerra Cavalcanti Sette; Edmundo Pessoa de Almeida Lopes
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

5.  A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges.

Authors:  Lopamudra Ray; Sunil Kumar Nanda; Anirban Chatterjee; Rajlaxmi Sarangi; Satyaki Ganguly
Journal:  Int J Appl Basic Med Res       Date:  2015 Jan-Apr

Review 6.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.

Authors:  Chen-Hua Liu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2022-07-25       Impact factor: 9.029

7.  Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil.

Authors:  Naylê Maria Oliveira da Silva; Fabiana Nunes Germano; Raul Andres Mendoza-Sassi; Hector Nicolas Seuánez; Marcelo Alves Soares; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2013-05-29       Impact factor: 4.099

8.  Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session.

Authors:  Edmundo Pessoa Lopes; Luis Henrique B C Sette; Jorge Bezerra C Sette; Carlos F Luna; Amaro M Andrade; Maviael Moraes; Paulo C A Sette; Roberto Menezes; Rui L Cavalcanti; Sergio C Conceição
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection.

Authors:  Taiga Otsuka; Yasunori Kawaguchi; Toshihiko Mizuta; Yasushi Ide; Futa Koga; Takanori Kumagai; Wataru Yoshioka; Kenichiro Murayama; Osamu Rikitake; Yuji Ikeda; Iwata Ozaki
Journal:  JGH Open       Date:  2017-11-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.